BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/10/2014 2:59:00 PM | Browse: 721 | Download: 859
Publication Name World Journal of Immunology
Manuscript ID 4975
Country Germany
Received
2013-08-06 10:38
Peer-Review Started
2013-08-06 21:45
To Make the First Decision
2013-09-09 14:24
Return for Revision
2013-09-12 11:33
Revised
2013-09-15 21:58
Second Decision
2013-11-01 16:50
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2013-11-03 11:15
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2013-11-14 16:52
Publish the Manuscript Online
2013-11-29 02:07
ISSN 2219-2824 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Autobiography
Article Title Tumor antigen and MHC expression in glioma cells for immunotherapeutic interventions
Manuscript Source Invited Manuscript
All Author List Christina Susanne Mullins, Alexander Walter, Michael Schmitt, Carl-Friedrich Classen and Michael Linnebacher
Funding Agency and Grant Number
Corresponding Author Michael Linnebacher, PhD, Department of General Surgery, Molecular Oncology and Immunotherapy, University Hospital Rostock, Schillingallee 35, 18057 Rostock, Germany. michael.linnebacher@med.uni-rostock.de
Key Words Tumor antigens; Glioblastoma multiforme; Major histocompatibility complex molecules; Tumor models; Cell lines
Core Tip Expression of tumor-antigens and major histocompatibility complex (MHC)-machinery components was analyzed in a series of seven novel low-passage glioblastoma multiforme cell lines by flow cytometry in comparison to three commercially available standard lines. MHC class Ⅰ was always expressed, MHC class Ⅱ readily after interferon gamma treatment. All cell lines expressed at least two tumor antigens. No differences between newly-established and commercially available cell lines were observed. Since these novel cell lines are available in low-passages upon request, they are interesting tools for future development of immunotherapeutic strategies, associated screenings and the like.
Publish Date 2013-11-29 02:07
Citation Mullins CS, Walter A, Schmitt M, Classen CF, Linnebacher M. Tumor antigen and MHC expression in glioma cells for immunotherapeutic interventions. World J Immunol 2013; 3(3): 62-67
URL http://www.wjgnet.com/2219-2824/full/v3/i3/62.htm
DOI http://dx.doi.org/10.5411/wji.v3.i3.62
Full Article (PDF) WJI-3-62.pdf
Manuscript File 4975-Review.docx
Answering Reviewers 4975-Answering reviewers.pdf
Copyright License Agreement 4975-Copyright assignment.pdf
Institutional Review Board Approval Form or Document Ethics_Committee_20130805233901.pdf
Non-Native Speakers of English Editing Certificate 4975-Language certificate.pdf
Peer-review Report 4975-Peer review(s).pdf
Scientific Editor Work List 4975-Scientific editor work list.doc